EGFR and neoplasm: Rociletinib (CO‐1686), an orally active EGFR inhibitor, significantly reduced the lung tumor incidence rates in these mice.[22] In line with our in vitro findings, loss of agrin expression in the remaining tumor nodules after CO‐1686 treatment was observed in vivo (Figure 2G,H).